
Fibrobiologics Inc (FBLG) Stock Forecast & Price Target
Fibrobiologics Inc (FBLG) Analyst Ratings
Bulls say
FibroBiologics Inc. is positioned favorably due to its innovative fibroblast-based therapies aimed at addressing significant unmet medical needs in chronic diseases, with promising preliminary outcomes in wound healing and psoriasis treatment that may enhance its therapeutic portfolio. The company's extensive intellectual property estate and focus on scalable manufacturing could lead to reduced production costs and regulatory hurdles, bolstering its competitive advantage in the cell therapy market. As the company advances its manufacturing preparations for ongoing clinical trials and IND-enabling studies, there is potential for substantial progress in development timelines, which may positively impact investor sentiment and the overall valuation of its stock.
Bears say
FibroBiologics faces significant risks that could adversely impact its financial outlook, including the potential failure of its developmental candidates to achieve peak revenue estimates due to market size limitations and patient penetration rates. The company reported a net loss of $5.8 million for the third quarter of 2025, reflecting substantial financial difficulties alongside an over 80% decline in its stock price year-to-date, contrasting with an overall industry increase of 20%. Further compounding these challenges, the firm may struggle to secure the necessary capital to fund operations and continue program development, which could hinder its long-term viability.
This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.
Fibrobiologics Inc (FBLG) Analyst Forecast & Price Prediction
Start investing in Fibrobiologics Inc (FBLG)
Order type
Buy in
Order amount
Est. shares
0 shares